{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:44Z","timestamp":1783329344097,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201182","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:06:07Z","timestamp":1773939967000},"page":"201182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2576-4739","authenticated-orcid":false,"given":"Kiwon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonsung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeil","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Oh","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2411-9369","authenticated-orcid":false,"given":"Sun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201182_bib1","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.3390\/cancers14153653","article-title":"Advances in cutaneous squamous cell carcinoma management","volume":"14","author":"Burns","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201182_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biomedicines9020171","article-title":"Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic ampproaches","volume":"9","author":"Fania","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201182_bib3","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.3390\/ijms140612222","article-title":"UV radiation and the skin","volume":"14","author":"D'Orazio","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201182_bib4","article-title":"A comprehensive review of the role of UV radiation in photoaging processes between different types of skin","volume":"17","author":"Brar","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.omton.2026.201182_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114074","article-title":"Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them","volume":"204","author":"Garbe","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201182_bib6","article-title":"Immunotherapy and systemic treatment of cutaneous squamous cell carcinoma. Dermatol","volume":"11","author":"Aboul-Fettouh","year":"2021","journal-title":"Pract. Concept"},{"key":"10.1016\/j.omton.2026.201182_bib7","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201182_bib8","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.3390\/cancers13205134","article-title":"Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma","volume":"13","author":"Garc\u00eda-Sancha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201182_bib9","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.3390\/cancers15174312","article-title":"Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world experience from a Canadian comprehensive cancer centre","volume":"15","author":"Koch Hein","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201182_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.omton.2026.201182_bib11","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201182_bib12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201182_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.omton.2026.201182_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201182_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1340702","article-title":"Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment","volume":"15","author":"Lv","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201182_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00262-024-03675-9","article-title":"Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion","volume":"73","author":"Yu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201182_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201182_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00262-017-2014-y","article-title":"Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments","volume":"66","author":"Sangaletti","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201182_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201182_bib20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: from mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201182_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.omton.2026.201182_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omto.2023.08.013","article-title":"Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus","volume":"30","author":"Hong","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201182_bib23","article-title":"Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.omton.2026.201182_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage M1\u2013M2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201182_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201182_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201182_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2026.201182_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-417028-5.00006-5","article-title":"Macrophage activation and polarization as an adaptive component of innate immunity","volume":"120","author":"Locati","year":"2013","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.omton.2026.201182_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/hum.2020.050","article-title":"Generation of a novel oncolytic vaccinia virus using the IHD-W strain","volume":"32","author":"Shin","year":"2021","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:24:01Z","timestamp":1783326241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000585"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201182","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201182"}}